Pluristem
Israeli breakthrough company seeks to use cells to improve quality of life
The biotechnology company Pluri, is expanding its activities and establishing strategic collaborations for the development and marketing of food-tech and pharmaceutical products.
Israel's Tnuva partners with Pluristem to develop cultured cell-based meat
Israel: The 'Start-Up Nation' is now the 'Biotech Nation' - opinion
Pluristem CEO touts a new generation of medical treatments
Pluristem’s placenta cells induce body to create new blood cells - study
Pluristem's PLX-R18 aims to stimulate the regenerative potential of the bone marrow to enhance the production of all three blood cell lineages: hemoglobin, neutrophil and platelet counts.
Pluristem names members of coronavirus Steering Committee
The committee is composed of five prominent infectious diseases, critical care, internal medicine and pumonology specialists from around the world
Pluristem to enroll participants for GvHD treatment at Sourasky
"We have so far found no negative side effects from the use of the PLX-PAD cells in the treatment of steroid-refractory cGvHD."
Israeli and Emirati companies join forces to develop COVID-19 treatment
The Israeli-Emirati joint projects aim to utilize each company's strengths in order to achieve results that will integrate the expertise of both companies.
FDA clears Haifa-based Pluristem’s COVID-19 Expanded Access Program
More coronavirus patients who do not qualify for the company’s clinical trial will now be able to receive treatment
Pluristem joins CRISPR-IL to develop next-gen genome editing products
“We see cell therapy and gene editing as highly synergistic methods to treat and cure diseases using advanced technologies."
Israel’s Pluristem: 75% of treated COVID-19 patients off ventilators
The survival rate is 87.5%, Pluristem Therapeutics reported.
Israel's Pluristem FDA approved for study in treatment of severe COVID-19
Six critically ill coronavirus patients in Israel who were considered high-risk for mortality were treated with Pluristem and survived.
Israel's Pluristem secures €50m. EU financing to boost COVID-19 treatment
The financing is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the financial pillar of the European Union's Investment Plan for Europe.
Israeli COVID-19 treatment with 100% survival rate tested on US patient
After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.
Israeli COVID-19 treatment shows 100% survival rate - preliminary data
Not only have all the patients survived, according to Pluristem, but four of them showed improvement in respiratory parameters.
